Liver Cancer Drugs Market Growth and Innovations

Liver Cancer Drugs Market Growth and Recent Advancements

In 2023, the liver cancer drugs market was valued at $2.67 billion. By 2032, it is expected to grow significantly, reaching $9.94 billion with an impressive compound annual growth rate (CAGR) of 14.2% from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5146

Report Highlights

• Targeted therapies made up the largest portion of the market in 2022, accounting for 52% of the total share.
• Hospital pharmacies dominated distribution channels, capturing a significant 71% of the market share in 2022.
• North America emerged as the leading region, holding 34% of the market share in 2022.

CSIR’s Breakthrough in Liver Cancer Research – January 2024

The Central Drug Research Institute (CDRI), India, has made significant progress in liver cancer research through a collaborative study. The research focuses on the metabolic changes occurring in cells that could play a key role in preventing hepatocellular carcinoma (HCC), the most common type of liver cancer.

Conducted in partnership with CIMAP, CBMR, and CSIR-CDRI, the study highlights how cancer cells undergo a shift in metabolic programming. These alterations could pave the way for improved diagnostic and preventive strategies.

Led by Dr. Madhav Nilakanth Mugale of CSIR-CDRI, the research used an animal model to replicate the progression of HCC in humans. It identified critical changes associated with disease advancement, such as decreased body mass, elevated serum enzyme levels, and alterations in liver structure.

Published in the prestigious Elsevier journal, this study opens the door to developing targeted therapies based on metabolic reprogramming, offering hope for more effective treatments for liver cancer.

Liver Cancer Drugs Market Companies

• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Exelixis, Inc.
• Merck KGaA
• Pfizer Inc.
• Eisai Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/liver-cancer-drugs-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5146

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare